logo

For the Inventor, By the Inventor

Philadelphia, PA, United States of America

Bruno Calabretta

This inventor holds 7 USPTO granted patents and 3 published patent applications. Top assignees: Temple University, Thomas Jefferson University. Active years: 1992-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bruno Calabretta. Retrieved from https://idiyas.com/inventor/bruno-calabretta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 100.0

Average Co-Inventor Count = 1.8

ph-index = 5

Forward Citations = 261(Granted Patents)


Company Filing History:

goldMedal4 out of 423 
 
Temple University
 patents
silverMedal3 out of 538 
 
Thomas Jefferson University
 patents

Years Active: 1992-1999

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5989849 - Antisense of oligonucleotides to c-kit proto-oncogene and in vitro (1999-11-23),
2. 5817783 - DR-nm23 and compositions, methods of making and methods of using the same (1998-10-06),
3. 5734039 - Antisense oligonucleotides targeting cooperating oncogenes (1998-03-31),
4. 5652222 - Selective inhibition of leukemic cell proliferation by bcr-abl antisense (1997-07-29),
5. 5427916 - Method for predicting the effectiveness of antineoplastic therapy in (1995-06-27),
6. 5362631 - C-myb transfected T98G cells which produce GM-CSF and stem cell factor (1994-11-08),
7. 5098890 - Antisence oligonucleotides to c-myb proto-oncogene and uses thereof (1992-03-24),

Title: The Innovative Contributions of Bruno Calabretta

Introduction

Bruno Calabretta is a notable inventor based in Philadelphia, PA, with a significant impact in the field of biotechnology. He holds a total of 7 patents, showcasing his dedication to advancing medical science and technology. His work primarily focuses on oligonucleotides and their applications in treating hematologic disorders.

Latest Patents

Calabretta's latest patents include groundbreaking research on antisense oligonucleotides targeting the c-kit proto-oncogene. These oligonucleotides are designed to be complementary to the mRNA transcript of the human c-kit gene, allowing for selective inhibition of erythroid cell proliferation. This innovation is particularly relevant for conditions characterized by elevated hematocrit levels due to excessive erythrocyte production. Additionally, his work on DR-nm23 protein has led to the development of methods for tracking chronic myelogenous leukemia and detecting the onset of blast crisis phases in affected individuals.

Career Highlights

Throughout his career, Calabretta has been associated with prestigious institutions such as Temple University and Thomas Jefferson University. His research has contributed significantly to the understanding of hematologic neoplasms and the development of therapeutic strategies.

Collaborations

Calabretta has collaborated with esteemed colleagues, including Alan M Gewirtz and Tomasz Skorski, further enhancing the impact of his research through shared expertise and innovative ideas.

Conclusion

Bruno Calabretta's contributions to biotechnology and medicine through his patents and research collaborations highlight his role as a leading inventor in his field. His work continues to influence the development of targeted therapies for serious health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…